fda ends semaglutide shortage Novo Nordisk's officially concludes in the US, spelling major threat for weight loss drug compounders FDA declares semaglutide (Ozempic/Wegovy) shortage
Description
Two investigators (HW and TG) independently searched for clinical trials aiming at weight management treatment
Your provider will craft a treatment plan that aligns with your health aspirations, review lab results if required, and address any potential health concerns related to your weight management
You should not use this medicine if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis
The group will publish half-year results on August 6.
